High 18F-FDG uptake in PMAH correlated with normal expression of Glut1,HK1,HK2,and HK3

Abstract

Background

Primary macronodular adrenal hyperplasia (PMAH) is a rare cause of Cushing’s syndrome, characterized by functioning adrenal macronodules and variable cortisol production. Recently, we demonstrated a high 18F-FDG uptake in PMAH, an unexpected finding for a benign disorder.

Purpose

To investigate whether there is a correlation between 18F-FDG high uptake and the expression levels of the glycolytic pathway components GLUT1, HK1, HK2, and HK3 in PMAH.

Material and Methods

We selected 12 patients undergoing surgery for PMAH who had preoperatively undergone 18F-FDG PET/CT. mRNA and protein expression of the selected genes were evaluated in the adrenal nodules from patients who underwent surgery through quantitative RT-PCR and by immunohistochemistry, respectively.

Results

SUVmax in PMAH was in the range of 3.3–8.9 and the adrenal size was in the range of 3.5–15 cm. A strong correlation between 18F-FDG uptake and largest adrenal diameter was observed in patients with PMAH. However, no correlation between 18F-FDG uptake and GLUT1, HK1, HK2, HK3 mRNA, and protein expression was observed.

Conclusion

High 18F-FDG uptake is observed in the majority of PMAH cases. However, 18F-FDG uptake in PMAH is independent of the expression levels of GLUT1, HK1, HK2, and HK3. Further investigation is required to elucidate the molecular mechanisms underlying increased 18F-FDG uptake in PMAH.

Keywords

Primary macronodular adrenal hyperplasia 18F-FDG PET adrenal adults hyperplasia monoclonal antibodies Cushing’s syndrome

Get full access to this article

View all access options for this article.

References

Dudczak

Traub-Weidinger

. PET and PET/CT in endocrine tumours. Eur J Radiol 2010; 73: 481–493.

Ong

Jin

Song

. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol 2008; 49: 1145–1153.

Boland

Blake

Holalkere

. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. Am J Roentgenol 2009; 192: 956–962.

Metser

Miller

Lerman

. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006; 47: 32–37.

Shimizu

Oriuchi

Tsushima

. High [18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med 2003; 17: 403–406.

Lin

Helgans

. Adrenal hyperplasia in Cushing's syndrome demonstrated by FDG positron emission tomographic imaging. Clin Nucl Med 2002; 27: 516–517.

Alencar

Fragoso

Yamaga

. (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake. J Clin Endocrinol Metab 2011; 96: 3300–3301.

Cushing

. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Original publication 1932. Reprint: Obes Res 1994; 2: 486–508.

Kirchner

Powell

Lipsett

. Cushing’s syndrome: Nodular cortical hyperplasia of adrenal glands with clinical and pathological features suggesting adrenocortical tumor. J Clin Endocrinol Metab 1964; 24: 947–955.

10.

Newell-Price

. Cushing’s syndrome. Clin Med 2008; 8: 204–208.

11.

Lacroix

. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 245–259.

12.

Haberkorn

Ziegler

Oberdorfer

. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994; 21: 827–834.

13.

Brown

Leung

Kison

. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556–565.

14.

Mamede

Higashi

Kitaichi

. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005; 7: 369–379.

15.

Binderup

Knigge

Loft

. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16: 978–985.

16.

Yen

See

Lai

. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004; 45: 22–29.

17.

Izuishi

Yamamoto

Sano

. Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography. J Gastrointest Surg 2012; 16: 394–400.

18.

Fenske

Völker

Adam

. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 2009; 16: 919–928.

19.

Livak

Schmittgen

. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–408.

20.

McCarty

Miller

Cox

. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716–721.

21.

Antonini

Fragoso

Lacroix

. [Clinical and molecular aspects of the ACTH-independent bilateral macronodular adrenal hyperplasia]. Arq Bras Endocrinol Metabol 2004; 48: 620–636.

22.

Bourdeau

Stratakis

. Cyclic AMP-dependent signaling aberrations in macronodular adrenal disease. Ann N Y Acad Sci 2002; 968: 240–255.

23.

Yamada

Brink

Bissé

. Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol 2005; 32: 316–334.

24.

van Berkel A Rao

Kusters

. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med 2014; 55: 1253–1259.